Alembic Pharmaceuticals receives USFDA final approval for Dapsone Gel 5%

What Alembic announced

Alembic Pharmaceuticals Limited informed the stock exchanges on 26 June 2026 that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dapsone Gel, 5%. The company filed a press release with the NSE and BSE, and the filing was recorded on the exchanges at 13:40:20 UTC on the same day.

"Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%" – press release dated 26 June 2026.

USFDA approval details

The approved ANDA is deemed therapeutically equivalent to the reference listed drug (RLD) Aczone Gel, 5%, manufactured by Almirall, LLC. Dapsone Gel is indicated for the topical treatment of acne vulgaris. The approval follows the standard USFDA review process for generic products, confirming that Alembic’s formulation meets the agency’s requirements for safety, efficacy, and quality.

Alembic’s ANDA track record

With this latest approval, Alembic’s cumulative total of USFDA ANDA approvals rises to 244, of which 224 are final approvals and 20 are tentative approvals. This milestone underscores the company’s long‑standing focus on generic drug development and its capability to navigate stringent regulatory pathways across multiple markets.

Key facts at a glance

Why this matters for investors

The approval adds another US‑regulated product to Alembic’s portfolio, reinforcing its reputation as a globally compliant generic manufacturer. USFDA clearance can facilitate entry into the large U.S. dermatology market, potentially expanding revenue streams without the need for new clinical trials. However, the filing does not disclose commercial launch plans, pricing, or expected sales contribution, so investors should await further operational updates.

Conclusion

Alembic Pharmaceuticals has secured USFDA final approval for Dapsone Gel 5%, its 244th ANDA approval, highlighting the firm’s robust regulatory track record. While the approval strengthens the company’s product pipeline, details on market rollout and financial impact remain to be communicated in future disclosures.